Objective: Evaluate if vascular normalization with an antiangiogenic monoclonal antibody improves detection of melanoma using fluorescently labeled antibody-based imaging.
INTRODUCTION
Cutaneous malignancies comprise more than twothirds of newly diagnosed cancers in the United States, with greater than 1 million cases diagnosed each year. 1 Although melanoma makes up only 3% of all skin cancers, it accounts for 83% of skin cancer deaths. 2 Despite the onset of novel therapeutics, melanoma incidence and mortality rates have been on the rise. [3] [4] [5] Inadequate surgical margins can lead to the development of local recurrence and distant metastasis, which is associated with a dismal prognosis. Approximately 40% to 60% of patients who develop recurrent melanoma die from their disease. 6, 7 We have shown previously that fluorescently labeled monoclonal antibody, panitumumab (Vectabix, Amgen, Thousands Oaks, CA), can detect melanoma using near infrared imaging. 8 Panitumumab binds to the extracellular domain of epidermal growth factor receptor (EGFR), which is a transmembrane tyrosine kinase involved in the regulation of cell differentiation and proliferation. [9] [10] [11] The role of EGFR in tumor progression and the correlation between EGFR overexpression and survival of patients with squamous cell carcinomas has been extensively studied. 10, [12] [13] [14] [15] [16] [17] [18] [19] However, EGFR expression by melanoma cells is less understood. Previous studies found EGFR expression levels in melanoma correlated with prognosis. [20] [21] [22] [23] [24] [25] Although melanocytes do not express EGFR, [23] [24] [25] there is an increase in EGFR expression because melanocytic lesions undergo progression from dysplasia to primary melanoma and ultimately to metastatic melanoma. 26 Clinically, EGFR expression has been found to correlate with sentinel Additional supporting information may be found in the online version of this article.
From the Department of Otolaryngology-Head and Neck Surgery(L.S., L.S.M., B.B.H., J.M.W.), the Department of Psychiatry (N.P.), Universi lymph nodes in patients with melanoma. 27 Furthermore, in metastatic melanoma there is increased activity of signaling pathways downstream of EGFR. 28 Melanoma cells also secrete high levels of vascular endothelial growth factor (VEGF). [29] [30] [31] Previous publications found that VEGF is critical to the angiogenesis of a tumor. [32] [33] [34] This led to the development and clinical use of bevacizumab (Avastin, Genentech, South San Francisco, CA), a monoclonal antibody targeting VEGF. [29] [30] [31] Compared to normal vasculature, tumor vasculature is circuitous with sporadic pericyte coverage, endothelial gaps, and variations in basement membrane thickness. 32, 35, 36 Subsequently, the vascular permeability and interstitial pressure increase. 32, 35, 36 Targeting VEGF induces vessel normalization, which is characterized by a reduction in the number and diameter of immature vessels, increased pericyte coverage, and decreased interstitial pressure. 32, 35, 36 This reduces drug egress and improves drug delivery. Bevacizumab in combination with other anticancer therapies has been shown to improve therapeutic efficacy of these agents in other malignancies. [37] [38] [39] [40] Therefore, we hypothesize that pretreatment with bevacizumab will increase the uptake of fluorescently labeled panitumumab in the melanoma tumors and improve tumor-to-background ratio (TBR).
MATERIALS AND METHODS

Cell Lines and Cell Culture
Melanoma cell lines A375 and SKMEL5 (ATCC, Manassas, VA) were maintained in Dulbecco's modified Eagle's medium, containing 10% fetal bovine serum; supplemented with 1% penicillin, streptomycin, and amphotericin B; and incubated at 378C in 5% CO 2 .
Animal Models
Nude and severe combined immunodeficient female mice, aged 4 to 6 weeks (Charles River Laboratories, Hartford, CT), were obtained and housed, experiments conducted, and animal euthanasia performed in accordance with the University of Alabama at Birmingham Institutional Animal Care and Use Committee guidelines (Animal Protocol Number: IACUC-09904). All institutional and national guidelines for the care and use of laboratory animals were followed. The mice received injections of 2 3 10 6 A375 or SKMEL5 cells suspended in 200 lL of phosphate-buffered solution into the dorsum of the ear. Each cohort included five mice.
Fluorescence Labeling of Monoclonal Antibodies
IRDye800CW (IRDye800CW-N-hydroxysuccinimide ester, LI-COR Biosciences, Lincoln, NB) is nontoxic to mice.
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IRDye800CW is a near-infrared imaging probe with a broad absorption (778 nm) and emission (794 nm) peaks. Antibody conjugation results in an absorption of 774 nm and an emission of 789 nm. 42, 43 Control IgG (Innovative Research, Peary Court Novi, MI) and panitumumab (Vectibix, Amgen) were labeled according to the manufacturer's instructions. Briefly, antibodies were incubated with IRDye800CW in 1.00 M potassium phosphate buffer (pH 9.0) for 2 hours at room temperature. Desalting spin columns (Pierce Biotechnology, Rockford, IL) removed the unconjugated dye. A final dye:protein ratio of 1.5 to 2.0 was determined using spectrophotometry. IN] ). Lysates were collected by centrifugation at 12000 3 g for 20 minutes at 408C. Bicinchoninic acid protein assay (Thermo Scientific, Rockford, IL) measured protein concentrations. Lysates with 10 lg of total protein were resolved by SDS polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. Membranes were incubated with the primary antibody (EGFR, Abcam, #15669 and VEGF, Abcam, #46154), washed, incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies, washed again, and detected by the Amersham ECL Western blotting detection system (GE Healthcare, Buckinghamshire, UK). Membranes were reprobed with horseradish peroxidaseconjugated mouse monoclonal antihuman beta-actin.
Histologic Analysis of Melanoma Tumors Grown In Vivo
Standard hematoxylin and eosin staining was done for all tumor specimens (Fig. 1 ). Human melanoma black (HMB-45) staining was chosen for its high specificity for melanoma. Immunohistochemical (IHC) analysis was performed to determine EGFR and Ki67 expression levels. Ki67 allowed for comparison of the cell viability between the groups.
Samples were rehydrated in xylene, 95% ethanol, and 70% ethanol. Antigen retrieval was in 1 mM EDTA, pH 9.0, for 5 minutes at 1008C. Samples were cooled at room temperature and blocked with 5% bovine serum albumin in Tris-buffered saline with Tween 20 for 5 minutes. Primary antibody, EGFR (Abcam, #27600), HMB-45 (Abcam, #787), or Ki67 antibody (Abcam, #15580) was applied at the concentrations recommended and incubated for 1 hour. Secondary antibody (Pierce (Thermo Fisher Scientific, Waltham, MA) goat anti-rabbit HRP, #32260) was applied for 40 minutes in a humidified chamber at room temperature. DAB (3, 3 0 -diaminobenzidine) substrate was applied to slides and allowed to incubate at room temperature until appropriate color developed. Samples were counterstained with Harris Hematoxylin (Fisher Scientific, Pittsburgh, PA) diluted 1:1 with tap water for 45 seconds. Finally, samples were dehydrated, counted with Permount (Fisher Scientific, Pittsburgh, PA), and allowed to dry overnight.
Described previously, semiquantitative analysis of EGFR was performed for both staining intensity and quality by two independent observers blinded to the cohorts and each other (L.S. and A.P.). Scoring values were assigned as follows: 0 5 none to < 10% of tumor cells staining, 11 5 light and incomplete staining in > 10% of tumor cells, 21 5 moderate and complete staining of > 10% of tumor cells, and 31 5 intense and complete staining > 10%. 44, 45 For the Ki67 scoring index, five sections of melanoma cells were selected. The melanoma cells were counted for the section, and the percentage positive for Ki67 was recorded.
In Vivo Near Infrared Imaging of Melanoma Tumors
Once tumor growth reached an average size of 8 3 8 mm, the mice were systemically injected (200 lg, tail vein) with IgGIRDye800CW or panitumumab-IRDye800CW (n 5 5). The combination group received systemic injection of bevacizumab (5 mg/kg, tail vein) 3 days prior to panitumumab-IRDye800CW (n 5 5). Previous studies found 3 days to be optimal for vessel normalization by bevacizumab. 46 Primary tumors were imaged daily and harvested on day 14. The tumors were serially sectioned, reducing the tumor volume in half with each resection. Tumor specimens 4-mm-thick were imaged and weighed. True positives based on imaging were histologically confirmed.
Quantification of Fluorescently Labeled Antibody Within Melanoma Tumors
The concentration of labeled antibody per gram of tumor (lg/ g) was calculated using normalized standards with known concentrations of panitumumab-IRDye800CW or IgG-IRDye800CW (Supp. Fig. S1B ). 46 Known concentrations of labeled antibody (0.0125-1.61 lg) were quantified by drawing a region of interest around the internal rim of the well and recording the mean pixel values. A linear standard of total fluorescence counts-to-microgram of dye was calculated. The tumor mean pixel fluorescence value acquired from a 4-mm-thick section of tumor was compared to the standard yielding a microgram of dye value. This was divided by the tumor weight (grams) and injected dose of IRDye800CW (200 lg) to yield a percent injected dose per gram (% ID/g).
The Pearl Impulse (LI-COR Biosciences, Lincoln, NB) is a closed system with a cooled charge-coupled camera. The TBR was derived by dividing the mean fluorescence of the tumor by the mean fluorescence of the background (mouse flank). 43 The LUNA (Novadaq, Toronto, Ontario, Canada) is an open-field imaging device using a charged coupled video camera to capture fluorescence (30 frames/second). 8, 47 LUNA was used for real-time fluorescent-guided resection of the tumors. Fig. 1 . Histologic assessment of A375 and SKMEL5 tumor specimens 14 days after systemic injection of panitumumab-IRDye800CW or pretreatment with bevacizumab followed by panitumumab-IRDye800CW. Initial staining was with H&E. EGFR immunohistochemical staining and reactivity analysis were performed. Membrane EGFR reactivity was based on the following scores: 0 5 no staining to < 10% of tumor cells staining, 11 5 light and incomplete staining in > 10% of tumor cells, 21 5 moderate and complete staining of > 10% of tumor cells, and 31 5 intense and complete staining > 10%. Ki67 staining was done to evaluate to cell viability after therapy. HMB-45 anti-melanoma antibody was performed to confirm melanoma tumor cells. EGFR 5 epidermal growth factor receptor; H&E 5 hematoxylin and eosin; HMB-45 5 human melanoma black-45.
Statistical Analyses
There were five measurements for each group at each time point. Mean and standard deviation (SD) were calculated and plotted for continuous variables. Bar graphs represent mean values and error bars represent SD. Statistical significance between groups was determined by a t test (two-sided) or if data did not normally distribute a Wilcoxon test. Statistical analysis was performed by the lead author (L.S.) and principal investigator (J.M.W.). A P < 0.05 was considered statistically significant. Western blot band intensities were quantified in triplicate using ImageJ (http://rsb.info.nih.gov/ij/) and normalized to beta-actin.
RESULTS
EGFR and VEGF Expression by Melanoma Cells
Western blot analysis was used determine EGFR and VEGF expression by the two melanoma cell lines in vitro. On western blot analysis, A375 cells were found to have a two-fold greater EGFR expression level compared to SKMEL5 cells (P < 0.001). Additionally, A375 cells were found to have six-fold greater VEGF expression compared to SKMEL5 cells (P < 0.0001) (Supp. Fig.  S1A ).
Immunohistochemical analysis was used to determine EGFR expression by the melanoma tumors (A375 and SKMEL5) in vivo. On IHC analysis, EGFR expression levels were found to be low to moderate for both cell lines, consistent with findings of previous publications (Fig. 1) . 48, 49 The mean EGFR score for A375 was 1.5 (6 0.5) and for SKMEL5 was 1.3 (6 0.45) (P 5 0.63). Interestingly, there was greater EGFR membrane staining for the A375 tumors compared to SKMEL5 tumors, which predominately had a cytoplasmic EGFR-staining pattern. For the A375 tumors, the mean EGFR expression for the panitumumab-only group was 1.7 (6 0.58) compared to 1.4 (6 0.55) for the combination therapy group (P 5 0.54). For the SKMEL5 tumors, the mean EGFR expression for the panitumumab-only group was 1.2 (6 0.41) compared to 1.3 (6 0.52) for the combination therapy group (P 5 0.84).
Ki67 staining of the tumors was used to determine viability and ensure that one-time treatment with either panitumumab or combination therapy did not result in significant cancer cell death. Using the Ki67 scoring index, there was no statistical difference between treatment groups or cell lines (Fig. 1) . For the A375 tumors, the mean in the panitumumab-only group was 68% (6 12%) compared to 54% (6 8%) in the combination therapy group (P 5 0.10). For the SKMEL5 tumors, the mean in the panitumumab-only group was 48% (6 7%) compared to 43% (6 8%) in the combination therapy group (P 5 0.32).
Near Infrared Fluorescent Imaging of Melanoma Tumors in Vivo
Daily imaging with the Pearl was done following systemic injection of either panitumumab-IRDye800CW or IgG-IRDye800CW (Fig. 2) . There was a greater mean fluorescence within the A375 melanoma tumors compared to background for the panitumumab (range 0.3-0.93) and the combination (range 0.22-0.84) groups at each imaging time point (P < 0.001) (Fig. 3) . Likewise, there was a greater mean fluorescence within the SKMEL5 melanoma tumors compared to background for the panitumumab (days 3-14, range 0.14-0.52) and the combination (days 1-14, range 0.17-0.76) groups (P < 0.001) (Fig. 3) . Whereas the combination therapy resulted in equivocal mean fluorescence in the SKMEL5 tumors compared to the A735 tumors (P 5 0.17), the panitumumab alone resulted in a lower mean fluorescence in the SKMEL5 tumors compared to the A375 tumors (P 5 0.03). Consistent with previous publications, panitumumab-IRDye800CW resulted in a greater mean fluorescence within the melanoma tumors at all time points compared to control IgG-IRDye800CW for both cell lines.
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Antiangiogenic Therapy Improves Contrast-Enhanced Tumor Delineation
To determine the ability of fluorescence imaging (using the Pearl Impulse) to differentiate tumor from normal tissue, TBR were calculated. For the A375 tumors, combination therapy (range 3.4-7.1) had statistically greater TBR than the panitumumab alone (range 3.2-5.0) (P 5 0.04) (Fig. 4) . For the SKMEL5 tumors, combination therapy (range 2.4-6.0) also had significantly greater TBR than the panitumumab alone (range 2.2-3.9) (P 5 0.02) (Fig. 4) . For both cell lines, the use of combination therapy resulted in greater TBR compared to the control IgG-treated group (P < 0.05).
Residual Tumor Detection in Melanoma Tumors In Vivo
Fluorescence-guided surgical resection was done with the LUNA at the time of tumor harvest. For the A375 tumors, the lowest tumor mass that could be differentiated from the background wound bed fluorescence was 1.5 mg for panitumumab alone and 0.20 mg for the combination group (Fig. 5) . For the SKMEL5 tumors, the lowest tumor mass that could be differentiated from the background wound bed fluorescence for panitumumab alone was 0.60 mg; for the combination group, it was 1.0 mg (Fig. 5) .
Quantification of Fluorescently Labeled Antibody Within Melanoma Tumors
The concentrations of labeled antibody within the A375 tumors was greater for the combination group (0.68 lg/g; 0.34% ID/g) compared to panitumumab alone (0.51 lg/g; 0.25% ID/g) (P 5 0.038) and IgG (0.02 lg/g; 0.01% ID/g) groups (P 5 0.001) (Fig. 6) . Similarly, the concentrations of labeled antibody within the SKMEL5 tumors was greater for the combination group (0.35 lg/ g; 0.17% ID/g) compared to panitumumab alone (0.17 lg/ g; 0.08% ID/g) and IgG (0.16 lg/g; 0.08% ID/g) groups (P < 0.05) (Fig. 6) .
DISCUSSION
Surgical resection of melanoma remains a challenge because the disease is often nonpalpable; margins are determined based on tumor thickness; and frozen section analysis is unreliable. As a result, there is a need for improvements in melanoma detection to improve survival and reduce the morbidity associated with resection. Currently, there is no cancer-specific contrast agent available for use in the clinic or the operating room for melanoma. Development of an imaging agent that can Fig. 2 . Imaging of mice with ear melanoma xenografts (A375 or SKMEL5) was done with the Pearl device (closed system with a cooled charge-coupled camera) (LI-COR Biosciences, Lincoln, NB). Imaging was done daily (select days shown) following systemic injection of either panitumumab-IRDye800CW or IgG-IRDye800CW (200ug, tail vein). To examine the effect of pretreatment with bevacizumab on panitumumab delivery, the bevacizumab (5 mg/kg) was injected 3 days prior to administration of panitumumab-IRDye800CW.
be used in real time to detect melanoma cells has the potential to reduce positive margins and improve outcomes.
During in vivo imaging, the A375 tumors had greater mean fluorescence and concentration of panitumumabIRDye800CW compared to SKMEL5 tumors. This is due to variations in the expression levels and cellular location of EGFR between the cell lines. In vitro, the A375 cells had two-fold greater EGFR expression levels compared to SKMEL5 cells. In vivo, EGFR is predominately on the cell surface of A375 tumors cells compared to intracytoplasmic for the SKMEL5 tumor cells. Therefore, the higher fluorescence in the A375 tumors is likely due to greater availability (expression levels and membrane location) of the EGFR for panitumumab-IRDye800CW binding.
The effect of antiangiogenic therapy on the uptake of fluorescently labeled antibodies within melanoma tumors was evaluated by pretreating with bevacizumab. Fig. 4 . The fluorescence for the tumor-tobackground ratio was calculated using images obtained on the Pearl device (LI-COR Biosciences, Lincoln, NB) of mouse ear xenografts (A4375 and SMEL5). Bars, standard deviation; statistical significance by unpaired t test. *P < 0.05. TBR 5 tumor-to-background ratio. Fig. 3 . Graphical representation of fluorescence within the mouse ear melanoma xenografts (A375 and SKMEL5) on days 3, 6, 9, and 12 via imaging with the Pearl device (LI-COR Biosciences, Lincoln, NB). Column, mean for treatment group (n 5 5); bars, standard deviation; statistical significance by unpaired t test. *P < 0.05. **P < 0.01. ***P < 0.001.
When comparing the mean fluorescence of the A375 melanoma tumors, the combination therapy group had a similar mean fluorescence to that of the panitumumabIRDye800CW-only treatment group. However, in the SKMEL5 tumors, there was a greater mean fluorescence within the melanoma tumors of the combination therapy group compared to the panitumumab-IRDye800CW-alone group. These findings suggest that through vessel normalization and prevention of drug egress, pretreatment with bevacizumab results in improved delivery of pantintumab-IRDye800CW into melanoma tumors with lower EGFR expression. [53] [54] [55] Similar to findings in previous publications, proliferation of SKMEL5 in vitro and in vivo was lower compared to A375. 56 Because the SKMEL cells are proliferating at a slower rate, we anticipated that they would secrete lower concentrations of growth factors. This was confirmed with western blot analysis, which found A375 to have a six-fold greater VEGF expression compared SKMEL5 cells. With less VEGF available, administration of the same dose of bevacizumab will have a greater impact on downstream pathways, including vessel normalization, in SKMEL5 tumors compared to A375 tumors. Previously, SKMEL5 cells were found to be more sensitive to survivin inhibition, whereas another investigation found SKMEL5 cells were more sensitive than A375 cells to treatment with sorafenib, a VEGF and Braf inhibitor with antiangiogenic and kinase inhibition properties. 57 Although these agents target different pathways, they support the findings in our study that SKMEL5 cells are more sensitive to the effects of therapy. Additionally, both bevacizumab and sorafenib inhibit VEGF and subsequently induce vessel normalization. 32, 56, 58 These differences in A375 and SKMEL5 behavior are multifactorial and likely due to variations in proliferation rates, microvessel density, behavior of tumor endothelial and pericyte cells, and EGFR turnover/internalization rates.
We also investigated the ability of fluorescence imaging to delineate tumor from normal tissue by calculating TBR. In vivo, we found pretreatment with bevacizumab resulted in greater TBR for the combination therapy groups compared to panitumumabIRDye800CW-only treatment groups in both cell lines. These findings demonstrate that pretreatment with bevacizumab improves tumor-specific uptake of panitumumab-IRDye800CW relative to normal tissue. The ability to differentiate tumor from normal tissue is important for improving detection of residual disease; reducing positive margin rates; and preserving normal, uninvolved tissues.
Clinical translation has the potential to improve early detection rates and surgical resection of melanoma. The near infrared spectral range of IRDye800CW (700-900 nm) decreases artifact of autofluorescence and improves depth of penetration. 8, 59, 60 The use of agents already approved by the U.S. Food and Drug Administration (FDA) (panitumumab) and equipment currently available in the operating room (LUNA, Novadaq) allow for a faster transition from preclinical to clinical and for more cost-effective implementation.
CONCLUSION
Molecularly targeted antibodies for cancer treatment are rapidly evolving. With the increased interest in fluorescent optical imaging probes and devices, the potential for significant improvements in intraoperative surgical techniques and identification of residual disease exist. Identifying which agents and combination therapy provide the greatest TBR, and subsequently greatest specificity and sensitivity, is important in the translatability of these agents. In vivo, pretreatment with bevacizumab prior to administration of panitumumab-IRDye800CW improved the TBR compared to panitumumab-IRDye800CW alone. In addition to its improved tumor localization, it is FDAapproved, making it an optimal antibody for clinical translation. 43 To our knowledge, this is the first study to investigate the effects of bevacizumab on the uptake of monoclonal antibodies targeting EGFR in melanoma tumors. With the rising incidence of melanoma and high mortality, novel methods of detection are paramount to improving outcomes.
